vs
DYNAVAX TECHNOLOGIES CORP（DVAX）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
BRC Group Holdings, Inc.的季度营收约是DYNAVAX TECHNOLOGIES CORP的2.0倍（$188.3M vs $94.9M），BRC Group Holdings, Inc.净利率更高（47.9% vs 28.4%，领先19.6%），DYNAVAX TECHNOLOGIES CORP同比增速更快（17.7% vs -21.9%），过去两年DYNAVAX TECHNOLOGIES CORP的营收复合增速更高（30.6% vs -15.4%）
Dynavax Technologies Corp是一家处于商业化阶段的生物制药企业，专注于研发和生产针对传染病的创新疫苗及免疫疗法，核心上市产品为成人乙肝疫苗Heplisav-B，主要市场覆盖北美与欧洲，同时拥有多款针对未满足公共卫生需求的在研产品。
DVAX vs RILY — 直观对比
营收规模更大
RILY
是对方的2.0倍
$94.9M
营收增速更快
DVAX
高出39.5%
-21.9%
净利率更高
RILY
高出19.6%
28.4%
两年增速更快
DVAX
近两年复合增速
-15.4%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $94.9M | $188.3M |
| 净利润 | $26.9M | $90.3M |
| 毛利率 | — | 79.5% |
| 营业利润率 | 22.4% | 32.3% |
| 净利率 | 28.4% | 47.9% |
| 营收同比 | 17.7% | -21.9% |
| 净利润同比 | 53.0% | 1710.8% |
| 每股收益（稀释后） | $0.21 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DVAXRILY
| Q4 25 | — | $188.3M | ||
| Q3 25 | $94.9M | $215.3M | ||
| Q2 25 | $95.4M | $188.2M | ||
| Q1 25 | $68.2M | $197.2M | ||
| Q4 24 | $72.0M | $241.0M | ||
| Q3 24 | $80.6M | $225.5M | ||
| Q2 24 | $73.8M | $256.0M | ||
| Q1 24 | $50.8M | $263.4M |
净利润DVAXRILY
| Q4 25 | — | $90.3M | ||
| Q3 25 | $26.9M | $91.1M | ||
| Q2 25 | $18.7M | $139.5M | ||
| Q1 25 | $-96.1M | $-10.0M | ||
| Q4 24 | $7.0M | $-5.6M | ||
| Q3 24 | $17.6M | $-284.4M | ||
| Q2 24 | $11.4M | $-433.6M | ||
| Q1 24 | $-8.7M | $-49.2M |
毛利率DVAXRILY
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 83.7% | ||
| Q2 25 | — | 81.3% | ||
| Q1 25 | — | 81.4% | ||
| Q4 24 | — | 79.8% | ||
| Q3 24 | — | 82.1% | ||
| Q2 24 | — | 84.5% | ||
| Q1 24 | — | 85.3% |
营业利润率DVAXRILY
| Q4 25 | — | 32.3% | ||
| Q3 25 | 22.4% | 30.4% | ||
| Q2 25 | 15.1% | 5.7% | ||
| Q1 25 | -34.7% | -31.2% | ||
| Q4 24 | -2.3% | -69.2% | ||
| Q3 24 | 12.5% | -36.4% | ||
| Q2 24 | 7.0% | -90.8% | ||
| Q1 24 | -35.0% | -6.1% |
净利率DVAXRILY
| Q4 25 | — | 47.9% | ||
| Q3 25 | 28.4% | 42.3% | ||
| Q2 25 | 19.6% | 74.1% | ||
| Q1 25 | -141.0% | -5.1% | ||
| Q4 24 | 9.8% | -2.3% | ||
| Q3 24 | 21.8% | -126.1% | ||
| Q2 24 | 15.4% | -169.4% | ||
| Q1 24 | -17.2% | -18.7% |
每股收益（稀释后）DVAXRILY
| Q4 25 | — | $2.78 | ||
| Q3 25 | $0.21 | $2.91 | ||
| Q2 25 | $0.14 | $4.50 | ||
| Q1 25 | $-0.77 | $-0.39 | ||
| Q4 24 | $0.07 | $-0.01 | ||
| Q3 24 | $0.12 | $-9.39 | ||
| Q2 24 | $0.08 | $-14.35 | ||
| Q1 24 | $-0.07 | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $160.2M | $226.6M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $534.1M | $-171.5M |
| 总资产 | $946.5M | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DVAXRILY
| Q4 25 | — | $226.6M | ||
| Q3 25 | $160.2M | $184.2M | ||
| Q2 25 | $99.1M | $267.4M | ||
| Q1 25 | $51.7M | $138.3M | ||
| Q4 24 | $95.9M | $146.9M | ||
| Q3 24 | $119.3M | $159.2M | ||
| Q2 24 | $112.5M | $236.9M | ||
| Q1 24 | $132.0M | $190.7M |
总债务DVAXRILY
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益DVAXRILY
| Q4 25 | — | $-171.5M | ||
| Q3 25 | $534.1M | $-260.5M | ||
| Q2 25 | $494.2M | $-351.7M | ||
| Q1 25 | $530.9M | $-496.8M | ||
| Q4 24 | $596.8M | $-488.2M | ||
| Q3 24 | $681.4M | $-497.6M | ||
| Q2 24 | $642.8M | $-218.3M | ||
| Q1 24 | $618.5M | $228.4M |
总资产DVAXRILY
| Q4 25 | — | $1.7B | ||
| Q3 25 | $946.5M | $1.7B | ||
| Q2 25 | $918.4M | $1.5B | ||
| Q1 25 | $945.9M | $1.5B | ||
| Q4 24 | $986.3M | $1.8B | ||
| Q3 24 | $1.1B | $2.2B | ||
| Q2 24 | $1.0B | $3.2B | ||
| Q1 24 | $986.6M | $5.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $33.8M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $32.6M | — |
| 自由现金流率自由现金流/营收 | 34.4% | — |
| 资本支出强度资本支出/营收 | 1.3% | — |
| 现金转化率经营现金流/净利润 | 1.26× | 0.29× |
| 过去12个月自由现金流最近4个季度 | $80.5M | — |
8季度趋势，按日历期对齐
经营现金流DVAXRILY
| Q4 25 | — | $26.2M | ||
| Q3 25 | $33.8M | $-60.6M | ||
| Q2 25 | $23.4M | $-25.6M | ||
| Q1 25 | $-19.6M | $184.0K | ||
| Q4 24 | $53.0M | $-2.7M | ||
| Q3 24 | $19.5M | $19.5M | ||
| Q2 24 | $10.7M | $111.5M | ||
| Q1 24 | $-16.7M | $135.4M |
自由现金流DVAXRILY
| Q4 25 | — | — | ||
| Q3 25 | $32.6M | — | ||
| Q2 25 | $22.0M | — | ||
| Q1 25 | $-23.6M | — | ||
| Q4 24 | $49.5M | — | ||
| Q3 24 | $18.1M | — | ||
| Q2 24 | $9.9M | — | ||
| Q1 24 | $-17.4M | — |
自由现金流率DVAXRILY
| Q4 25 | — | — | ||
| Q3 25 | 34.4% | — | ||
| Q2 25 | 23.0% | — | ||
| Q1 25 | -34.6% | — | ||
| Q4 24 | 68.8% | — | ||
| Q3 24 | 22.5% | — | ||
| Q2 24 | 13.5% | — | ||
| Q1 24 | -34.3% | — |
资本支出强度DVAXRILY
| Q4 25 | — | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.5% | — | ||
| Q1 25 | 5.8% | — | ||
| Q4 24 | 4.8% | — | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 1.1% | — | ||
| Q1 24 | 1.5% | — |
现金转化率DVAXRILY
| Q4 25 | — | 0.29× | ||
| Q3 25 | 1.26× | -0.66× | ||
| Q2 25 | 1.25× | -0.18× | ||
| Q1 25 | — | — | ||
| Q4 24 | 7.52× | — | ||
| Q3 24 | 1.11× | — | ||
| Q2 24 | 0.94× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DVAX
| HEPLISAVB | $90.0M | 95% |
| US Department Of Defense | $4.7M | 5% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
